Ligand to Report Third Quarter 2017 Results on November 9th
Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments
Ligand to Host Analyst Day on November 14th in New York City
Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Appoints Dr. Nancy Gray to its Board of Directors
Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
Ligand Reports Second Quarter 2017 Financial Results
Ligand to Report Second Quarter 2017 Results on August 7th
